Published online Dec 7, 2023. doi: 10.3748/wjg.v29.i45.5962
Peer-review started: August 1, 2023
First decision: September 30, 2023
Revised: October 30, 2023
Accepted: November 17, 2023
Article in press: November 17, 2023
Published online: December 7, 2023
Processing time: 121 Days and 15 Hours
More evidence is needed regarding the association between muscle strength and metabolic dysfunction-associated fatty liver disease (MAFLD) and only a few cross-sectional studies have shown that sarcopenia was associated with liver fibrosis in patients with MAFLD. In response to the increasing public health burden of MAFLD in Asia, we investigated the association between muscle strength and MAFLD using a Korean nationally representative database.
A recent introduction has been made regarding a new definition: MAFLD. Importantly, MAFLD is associated with increased all-cause mortality and advanced fibrosis in MAFLD had a higher all-cause mortality risk than that in non-alcoholic fatty liver disease. However, the link between muscle strength and MAFLD is not well studied.
We aimed to investigate the association between muscle strength and MAFLD in the general population in Korea. Additionally, we sought to study the risk of liver fibrosis in patients with MAFLD according to muscle strength.
This study used data from the Korea National Health and Nutrition Examination Survey. Muscle strength was assessed using relative handgrip strength and the participants were categorized into muscle strength quartiles. We performed multivariable logistic regression analysis to evaluate the association between muscle strength and the risk of MAFLD and calculated the odds ratios and 95% confidence intervals.
Twenty-nine point three per cent of the participants had MAFLD. The lowest quartile was significantly associated with higher prevalence of MAFLD for all participants, sexes, and age groups. In patients with MAFLD, the odds of severe liver fibrosis were higher in Q1 than in other groups (Q2–Q4). However, causality should be investigated in future studies.
The nationwide study of the Korean adult population revealed that low muscle strength was associated with a dose-dependent higher risk of MAFLD in all participants and subgroups. Additionally, low muscle strength is associated with a high probability of liver fibrosis in patients with MAFLD. The identification and management of low muscle strength may play a crucial role in preventing MAFLD and liver fibrosis.
Prospective cohort or randomized controlled trials are needed to confirm the relationship between muscle strength and MAFLD. Future studies should focus on whether physical activity can prevent or reverse MAFLD and liver fibrosis in patients with MAFLD.